KYNB Kyntra Bio, Inc.
$3.20
Kyntra Bio, Inc. Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Conference Operator
Operator
Thank you for standing by and welcome to Kintra Bio's third quarter 2026 earnings conference call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. To remove yourself from the queue, you may press star 1-1 again. I would now like to hand the call over to Gaia Shamis. Please. Go ahead.
Gaia Shamis
LifeSci Advisors
Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss Kintra Bio's third quarter 2026 financial and business results. I'm Gaia Shamis from LifeSci Advisors. Joining me on today's call are Thane Wettig, Chief Executive Officer, David DeLucia, Chief Financial Officer, Dr. Carrie Brownstein, Project Chief Financial Officer, and Carol Gaddum. and Vice President of Product Development. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about Kintra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kintra Bio's filing with the SEC, including our most recent Form 10-K and Form 10-Q. Kintra Bio does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting the company's financial results and business update and a webcast of today's conference call can be found on the investor section of Kintra Bio website at www.kintrabio.com. With that, I would like to turn the call over to CEO Thane Wettig. Thane? Thank you, Gaia.
Thane Wettig
Chief Executive Officer
Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. On today's call, I will provide important updates on the company's transformation and the direction of Kintra Bio moving forward. And then David DeLucia, our CFO, will review the financials, after which we will open the call for your questions. Turning to slide three, in the fourth quarter of 2026, the company completed a preplanned interim analysis of the Phase II monotherapy trial of FG3246, an antibody drug conjugate targeting CD46, a metastatic castration-resistant prostate cancer, and FG3180, a companion PET imaging agent. Unfortunately, based upon insufficient interim efficacy results that did not meet the threshold required to support continued development, We have made the decision to terminate the Phase 2 study of FG3246 and FG3180. I would like to provide context underpinning our decision to terminate the program. In May of 2023, we entered into the license agreement with Fortis Therapeutics based on the potential of the CD46-targeted ADC and its companion PET imaging agent in MCRPC. In April of 2024, results from the Phase 1 monotherapy study of FG3246 demonstrated a median radiographic progression-free survival, or RPFS, of 8.7 months in the heavily pretreated population. Our subsequent Phase II monotherapy study was designed with the intention to determine whether we could improve upon those results with a target of at least 10 months of median RPFS at final analysis, a target that was based not only on currently available therapies but also based on data from products in development. Following the review of data from the planned interim analysis, the efficacy findings do not support continuing to advance the program. Not only do the data point to a challenging path forward, achieving the minimum of 10 months of meeting RPFS in both an all-comers population and in a CD46 enriched population, recently disclosed competitive data indicates that the clinical bar is simply getting higher. We therefore made the decision to terminate the development of FG3246 and FG3180. As a result of this decision, the company is returning the asset to Fortis and has commenced wind-down activities. In addition, we will save approximately $20 million in planned operating expenses across 2027 and 2028. Clearly, this was not the outcome we had hoped for, and on behalf of contra Bio, I would like to extend our sincere gratitude to the patients and their families clinical investigators, their research teams, and site personnel whose commitment and participation made this study possible. Turning to slide four, we highlight our evolution into a pure play rare disease company focused on the phase three development of Roxidustat for patients with anemia associated with lower risk myelodysplastic syndrome and high red blood cell transfusion burden, or HTV. Our phase three strategy is informed by the post hoc results from the Matterhorn study in the high transfusion burden population and reinforced by input from KOLs and a productive engagement with the FDA on the phase three study design. We believe that there is a substantial unmet need for a new treatment with a novel mechanism of action and oral routed administration that can demonstrate efficacy across the broad spectrum of patients suffering from anemia due to lower risk MDS. Additionally, we have transformed the company's balance sheet with the amendment of our NovaQuest Royalty Financing Agreement, which reduced our maximum payment obligation by $60 million and lowered our remaining royalty-backed payment obligations to only $15 million. Our simplified capital structure and current cash balance of over $44 million provides the company a strong financial foundation and the resources to continue to prepare for the initiation of the ROXA Duestat Phase III Development Program. The termination of the FG3246 and FG3180 program enables us to concentrate our resources on the defined Phase III Development Plan for Rocha-Duestat. We are currently on track to initiate this study in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise. I will discuss our conviction behind this focus and review the clinical evidence and plan Phase III trial design and subsequent slides. Moving on to the Rox-Dustat lower risk MDS program, slide six highlights the prevalence and unmet need associated with lower risk MDS. Approximately 74,000 people in the U.S. are living with MDS, including about 52,000 with lower risk disease and roughly 41,000 patients diagnosed with anemia, the hallmark symptom and main driver of morbidity of this condition. While additional therapies have become available over the past few years, patients who progress beyond first-line treatment continue to have limited options as these treatments require in-office injections or infusions with responses that are often not durable. Therefore, It stabilizes hip alpha, mimicking the body's natural response to low oxygen, leading to an increase in hemoglobin. Second, hip activation stimulates red blood cell production by increasing endogenous erythropoietin, improving iron availability, and supporting red blood cell maturation. And third and importantly, hip activates GATA1, a master Importantly, Roxidustat has been approved in more than 40 countries for anemia associated with chronic kidney disease, demonstrating not only important hemoglobin response, but also significantly fewer transfusions in the CKD patient population. In addition, over 1 million patients have been treated with Roxidustat worldwide since its first approval in 2019, reinforcing its efficacy and safety profile. In the following slides, I will provide a detailed review of the post-hoc analysis of patients from our previous Phase III Matterhorn study with a focus on patients with high transfusion burden using the International Working Group definition of four or more RBC units in two consecutive eight-week periods. We believe these results demonstrate Roxiducet's potential as a safe and effective oral treatment option for patients with lower-risk MDS. Slide 8 highlights previously disclosed results in the high transfusion burden population from the Matterhorn Phase III trial, demonstrating that treatment with roxidustat led to transfusion independence in 36% of patients for at least eight straight weeks within the first 28 weeks of the trial versus only 7% in the placebo group with a nominal p-value of 0.041. These results are highly similar to the pivotal trial results from the two most recently approved therapies for anemia associated with lower risk MDS. When we assessed eight-week RBC transfusion independence over 52 weeks in the high transfusion burden population, the corresponding rates were 45% for roxidustat and 13% for placebo with a highly similar nominal p-value of 0.043. The following slides provide additional supporting data of Roxidustat's effect on this high transfusion burden population. Slide 9 shows the potential durability of transfusion independence with treatment of Roxidustat versus placebo over extended periods of time. In the high transfusion burden subgroup, 36% of Roxidustat patients achieved at least 12 weeks of transfusion independence within 52 weeks versus only 7% with placebo, and at least 16 weeks of transfusion independence within 52 weeks in 18% of Roxidustat-treated patients versus 0% for placebo. On slide 10, when looking at hemoglobin levels over time, which is the underlying basis that enables transfusion independence to be achieved, there was a consistent and meaningful increase in hemoglobin in Roxidustat-treated patients versus placebo. Mean hemoglobin on Roxidustat rose by approximately one gram per deciliter from baseline and was sustained through week 28. while placebo remained near or slightly below baseline. These results reinforce the effect that roxidustat can have in the high transfusion burden patient population. We then further explored whether roxidustat has the potential to benefit patients regardless of ringside aeroblast or RS status, which is shown on slide 11. In the Matterhorn high transfusion burden patient group, we observed transfusion independent responses in both RS negative and RS-positive patients, 38% and 33%, respectively. These results were mimicked in the full analysis set, where 48% of RS-negative patients and 46% of RS-positive patients on roxidustat achieved eight-week RBC transfusion independence. This is extremely important as we think about the substantial unmet need in RS-negative patients and the potential placement of roxidustat in the treatment paradigm. I will touch more on this later in the presentation. On slide 12, we assessed patients who had previously received ESA therapy. Among high transfusion burden patients categorized as ESA refractory, 31% of Roxzustat-treated patients achieved at least eight weeks of transfusion independence within 28 weeks compared with none of placebo-treated patients with a nominal p-value of 0.040. As you can see, the roxidustat treatment effect versus placebo is more pronounced in the east of refractory population than in the east of naive population. We are highly encouraged by these results given that ESA refractory high transfusion burden patients from the Matterhorn study most closely mimic the inclusion criteria for our planned upcoming phase three study. Slide 13 highlights the efficacy of roxidustat in the high transfusion burden population by baseline EPO serum levels. Roxiducet achieved greater eight-week transfusion independence versus placebo in patients with baseline EPO serum levels both below 200 and above 200. This is consistent with the mechanism of action in treating anemia from lower risk MDS that does not rely solely on EPO. Slide 14 summarizes the safety findings from Matterhorn. In the overall study population, treatment emergent adverse events occurred in a similar proportion of roxidustat and placebo patients. When evaluating grade three or higher events, treatment with roxidustat was associated with a higher incidence relative to placebo, 38% versus 21%, with no individual grade three TEAE occurring in more than 5% of roxidustat treated patients. Moving to slide 15, we took a closer look at the Roxodustat safety profile in patients with high transfusion burden and believe it is consistent with the safety profile in the overall population. While grade three or higher TEAEs were more frequent in Roxodustat treated patients compared to placebo at 65% versus 27%, the rate of treatment discontinuation due to adverse events were similar between the two groups at 22% for Roxodustat and 20% for placebo. Turning to slide 16, we believe roxidustat has the potential to offer a differentiated treatment option in lower-risk MDS, specifically for patients who progress beyond first-line therapy. While recent approvals have expanded treatment options, these therapies have limitations in efficacy, durability, safety, and treatment burden. Both the spatter step and a metal step require an in-office injection or infusion, whereas roxidustat offers the convenience of oral administration three times per week. Notably, post-hoc results from the Matterhorn study suggest the potential for meaningful transfusion independence in patients with high transfusion burden across both RS-positive and RS-negative disease. This is especially relevant given Lusbatercept, the market-leading brand in the treatment of lower-risk MDS, has not demonstrated clinically differentiated efficacy in this RS-negative segment of the lower-risk MDS population and is not indicated for use in the second-line setting in RS-negative patients. Despite these limitations in the RS negative population, Luzbettercept is forecasted to achieve revenue of more than $2.5 billion in the US at the projected timing of a Roxidustat approval and launch, highlighting the substantial commercial potential in lower risk MDS. Primary research we have conducted with practicing hematologists and oncologists in the US indicates that Roxidustat has the potential to be a useful treatment option in both RS positive and RS negative patient segments. While we can't make direct comparisons across clinical trials, we believe that demonstrating similar efficacy across the entire patient population could position roxidustat favorably in the treatment paradigm of lower risk MDS. Moving to slide 17, as I mentioned, our target indication for roxidustat is for the treatment of anemia in patients with lower risk MDS who are refractory to or ineligible for prior ESA treatment. where we believe Roxadustat can raise the standard of care and address a significant unmet need across multiple treatment lines. We believe we also have an opportunity to capture first-line share in the RS-negative setting and to evaluate the potential to generate incremental data to further support the use of Roxadustat in this frontline RS-negative population, bolstering the overall commercial opportunity of Roxadustat. Turning now to the planned pivotal trial, are Phase III strategies informed by the post-hoc results from the Matterhorn study in the high transfusion burden population and reinforced by input from KOLs and a productive engagement with the FDA on the Phase III study design, which is shown on slide 18. In this double-blind placebo-controlled trial, patients with low-risk MDS and high transfusion burden who are refractory to and tolerant of or ineligible for ESA treatment will be randomized two-to-one to oral roxidustat versus placebo, each administered three times a week along with best supportive care. The primary endpoint is the rate of RBC transfusion independence over eight consecutive weeks during the first 24 weeks of the trial. Key secondary endpoints include 12-, 16-, and 24-week transfusion independence assessed over 48 weeks, as well as hematologic improvements in erythroid response specifically the proportion of patients whose transfusion requirements are reduced by 50% or greater from baseline. A planned interim analysis will be conducted once 50% of patients have completed 24 weeks of treatment or have discontinued treatment, which we expect will take place approximately 18 months after the initiation of the study. We have set the futility bar to a conditional power of less than 30%. If the Roxidustat Arm exceeds the futility bar, the study will progress through the primary analysis of 201 patients over 48 weeks. I will now review our development timeline for this program on slide 19. Our near-term priority remains the initiation of the phase three trial in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise. Looking ahead, we are targeting the phase three interim analysis in the second half of 2028, followed by the primary analysis in the first half of 2030. to summarize the Roxidustat opportunity in lower risk MDS on slide 20. With a substantial unmet need, no oral therapeutic options on the market or in late stage development, significant potential in the second line setting, and importantly in RS negative patients, along with an orphan drug designation, we view Roxidustat as a compelling commercial opportunity with blockbuster potential of approximately $1 billion in peak sales in the United States. A forecast that is informed by a rigorous external opportunity assessment conducted for us by ZS Associates. With that, I will now turn the call over to Dave to discuss the company's financials. Dave?
David DeLucia
Chief Financial Officer
Thank you, Thane. I'll begin with the amendment to our Ruralty Financing Agreement with NovaQuest Capital Management, summarized on slide 22. Under the amended agreement, the maximum aggregate payment obligation has been reduced from $125 million to $65 million, a decrease of $60 million. In the third quarter of 2026, we made an accelerated upfront payment of $42.6 million, bringing the total payments made to NovaQuest to $50 million. The remaining payments are capped at $15 million and will be funded from 50% of the revenue we receive from Astellas in the covered territories under the License Agreement excluding Japan. Once the remaining cap is reached, the amended agreement will terminate and we will retain subsequent avrento royalty revenue in the applicable Astellas territories. Overall, the amendment significantly reduced our remaining long-term obligations under the original agreement and simplifies the remaining go-forward payments to NovaQuest associated with the Estella's royalties. The amendment was highly accretive to contra Bio shareholders, generating an internal rate of return of over 26% based upon the new lowered forecasted obligations owed to NovaQuest. Now, turning to our financial results for the third quarter. For the third quarter of 2026, total revenue was $1.8 million compared to $1.1 million for the same period in 2025. Total operating costs and expenses for the third quarter of 2026 were $14.6 million compared to $6.5 million for the third quarter of 2025. R&D expenses for the third quarter of 2026 were $8.3 million compared to $1.2 million in the third quarter of 2025. SG&A expenses for the third quarter of 2026 were $5.8 million compared to $5.3 million in the third quarter of 2025. As a result of the termination of the Phase II study of FG3246 and FG3180, we are now forecasting a reduction of over $20 million in operating expenses across 2027 and 2028. During the third quarter of 2026, we recorded a net income from continuing operations of $0.2 million, or $0.04 net income per basic and diluted share, compared to a net loss of $13.1 million, or $3.25 net loss per basic and diluted share, one year ago. This was driven by a $14 million gain on debt restructuring from the execution of the amendment to our royalty financing agreement with Nova. Now shifting towards cash. As of September 30th, we reported $44.1 million in cash, cash equivalents, investments, and accounts receivable. Due to the termination of the FG-3246 and FG-3180 program, we now expect the company to have a cash runway into 2028, enabling us to continue to progress Roxidustat towards a Phase III trial initiation next quarter. We continue to have ongoing discussions with both strategic partners and external capital providers for the funding of the ROXADUSTAT phase 3 trial. Thank you, and I will now turn the call back over to Thane.
Thane Wettig
Chief Executive Officer
Thank you, Dave. We entered the final months of 2026 with a sharpened focus and strong momentum. Our immediate priority is the completion of the funding process for the phase 3 trial of ROXADUSTAT and the subsequent initiation of the study planned in the first quarter of next year. With that, I would like to now turn the call over to the operator for Q&A.
Conference Operator
Operator
As a reminder, to ask a question, you will need to press star 11 on your telephone. To remove yourself from the queue, you may press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Michael King. of Rodman and Brimshaw. Please go ahead, Michael. Hi, good afternoon, guys. Thanks for taking the questions.
Michael King
Analyst, Rodman & Renshaw
A couple of questions, first on 3246. Thane, do you guys plan on presenting any data of the results or we just should forget that? And I'm just wondering if there was any clues from... Thank you for your questions. First, in terms of disclosure, we will ensure that we work with Bahul Agarwal, who is the
Thane Wettig
Chief Executive Officer
PI at UCSF regarding disclosure. So I'm sure that results will be disclosed in some form at some point in time. I can't exactly say at what form or when. But we think this is important information for people to see. And I know that Dr. Egerwald feels the same way. In terms of on any clues related to CD46 expression, I'm going to ask Carol to handle that one. And if needed, pass it over to Carrie for additional comments. Carol?
Carol Gaddum
Vice President of Product Development
Thank you for the question. At this point, we have not analyzed the CD46 expression data. However, given the activity that we've seen in the all-commerce population, it won't support continuous development, but that data is not available at this point in time. Passing it on to Carrie for any additions.
Dr. Carrie Brownstein
Project Chief Financial Officer
Yeah, hi. Not too much extra, just we're going to continue to look at that data. I do think, as Thane pointed out, it is important that we analyze it and understand. But as Carol mentioned, the data overall just wasn't enough to support further investment.
Michael King
Analyst, Rodman & Renshaw
Okay, fair enough. The second question is on ROXA. And I'm just wondering, I know there's a substantial database of safety and efficacy in the dialysis population. But in high-risk MDS, the post hoc numbers are fairly small. And if you look at that relative to your current capital position, does it set up this tension that you're going to run into when you're in discussions with a potential partner or other funding source? regarding that fact, and is it going to make your discussions a challenge, or would you actually consider maybe running a small sort of introductory or preliminary study to get some greater efficacy, even if it's a single arm open label study to bolster the efficacy argument for Roxa? I hope that wasn't too convoluted, but I think you know where I'm going.
Thane Wettig
Chief Executive Officer
No, I know where you're going, Mike. And I'll start it off, and then I'll hand it over to Carrie. And just before Carrie takes over, just FYI, because I'm not sure how broadly she's been introduced, Carrie actually was the VP and the head of the myeloid group at Celgene during the development of loose fat receptor. And so not only does she know a tremendous amount about lower risk MDS and drug development in this space, but we're really fortunate to have her as part of the team. In terms of getting at your question, Mike, I think that there are a couple of ways that one could go. One could perhaps take a step back and do what you're suggesting. I think that that then comes at a cost of time and money. We think we've got a pretty important advantage being the only oral agent that has the potential to be in late stage development. There are a couple of other oral agents that are entering phase two. So we would have, let's say, a two to three year head start on them. I think that we've got enough data. Honestly, even though you referenced it, it's in a small subgroup. I think that the way that data all hangs together, whether it be high transfusion burden patient population, the ease of refractory patient population, regardless of the of the eco level, everything kind of hangs in there. And we know that the Roxdeuce debt raises hemoglobin and we know that if you raise hemoglobin, then you're going to reduce the requirement for transfusions. We saw it in the CKD population, and we saw it in the subset analysis associated with the Matterhorn trial. And so if we were seeing kind of a data signal here that wasn't reinforced by another data signal, then I think we might say, hey, let's take a step back and maybe do some additional clinical work, perhaps as you referenced, perhaps an open label single log trial I just don't think we've learned that much, honestly, relative to planning to go forward into the phase three trial. And I can say that, you know, without getting into specifics, that there are parties who look at our Matterhorn data and are highly interested in what that data tells us. Carrie, why don't you take over from there?
Dr. Carrie Brownstein
Project Chief Financial Officer
Yeah, I mean, I think you said everything that needed to be said. I think that going back and doing another phase two to further bolster the data package that we have to support a phase three is one way to go. But I agree with Thane. Even though the data set is small, every way we look at it, as well as even if we include some of the other patients with slightly lower transfusion burden, it's pretty... strong evidence for the drug to be working in this patient population. And again, I don't see us gaining too much extra from adding additional patients to the analysis.
Michael King
Analyst, Rodman & Renshaw
Okay. Thanks for the call. I'll jump back in the queue.
David DeLucia
Chief Financial Officer
Thanks, Mike.
Conference Operator
Operator
Thank you. Thank you. Our next question comes from the line of Jay Olson of Oppenheimer. Please go ahead, Jay.
Jay Olson
Analyst, Oppenheimer
Oh, hey, thanks for providing this update and taking the questions. With the phase three study initiation now planned for the first quarter next year, what operational work remains before you can get started? And we appreciate the study timeline you shared. Can you just talk a little more about the rate of enrollment that investors should expect? And will the planned interim analysis be strictly a utility assessment or would it also provide an opportunity to accelerate development. And then I had a follow-on, if I could, please.
Thane Wettig
Chief Executive Officer
Yeah. Thanks, Jay. Good to hear from you. I'll go ahead and kick it off. And if I leave anything out, I'll ask Carrie and Carol to add in. In terms of the operational work that remains, you know, the team has been really active over the past several months, you know, either related to interactions with the agency regarding information requests, signing up the CRO, working with other vendors that obviously are critical to get a phase three trial off the ground. And so really the rate limiter for us is going to be the funding for the trial. And so the operational work has been largely complete, not entirely complete, but largely complete. And then we're gonna continue to do pieces of that as we go down then the capital raise process. In terms of enrollment, What we are assuming is 201 patients. It will take 24 months to enroll. We would sign up anywhere from 100 to 110 sites. And so at steady state, we would assume that the enrollment rate is roughly one-tenth of one patient per site per month. We think we'll be conservative. If you look at the METALYST trial for the spattercept, which Carrie was responsible for, They enrolled 220-plus patients in about 17 months. The Medelstead enrolled 180 patients in roughly 22 months or so. And so, you know, given the much greater awareness of lower risk MDS, the fact that we've got an oral option, the fact that patients could have been on the Spattercept or Medercept before going onto either ROX or placebo in our trial, we think that there are a number of factors that would enable us to beat that 24-month , but that's the current assumption. And then, Jay, the last question, what was that?
Jay Olson
Analyst, Oppenheimer
Just related to the interim analysis and whether that's utility only or could you use that to accelerate development?
Thane Wettig
Chief Executive Officer
Yeah, it's utility only. We won't be looking at it from kind of an early stopping perspective. It is strictly utility.
Jay Olson
Analyst, Oppenheimer
Okay, thank you. Thanks for all the additional color. And if I could ask one One follow-up, please.
Thane Wettig
Chief Executive Officer
Let me just ask Carrie or Carol if there are any additional comments that they would like to add.
Carol Gaddum
Vice President of Product Development
No comments from my side. Okay.
Thane Wettig
Chief Executive Officer
Yeah, go ahead, Jay.
Jay Olson
Analyst, Oppenheimer
Your strategy highlights the advantages of an oral option across RS subtypes with potential expansion into first-line RS-negative disease. Based on your market research with physicians, where do you see the strongest initial adoption of Roxidustat?
Thane Wettig
Chief Executive Officer
Yeah, great question. I'm going to turn that over to Carol. She was the point person in working with ZS Associates a few months ago to do a pretty comprehensive opportunity assessment. We talked to 20 hematologists, oncologists in the U.S., a mix of academic and community-based physicians. We also spoke with five U.S.-based payers. So, Carol, why don't I turn it over to you?
Carol Gaddum
Vice President of Product Development
Thank you for the question. So initial strong adoption, we certainly see in the 2L plus setting in RS negative after ESA or loose batter set. There is a particularly high unmet need for an oral option in the community setting where most of the treatment here is taking place, where this oral option could really benefit patients, especially the elderly ones with some mobility challenges. And then from there on, really an opportunity to expand more broadly across and the 2L setting, agnostic of RS status and then to Thane's earlier point, also into a frontline within selected patients where current treatment options aren't providing benefit.
Thane Wettig
Chief Executive Officer
Yeah, and maybe just one more comment on that. The preference share stated by the clinicians in the research would say that we could kind of carve out a high single-digit frontline share primarily because of the fact that we are the only oral option available. And there's a lot of value in that frontline share just based upon how many patients stay in frontline therapy. Some of them don't end up progressing to second-line therapy. And the physicians have told us over and over again is that based upon the health status of the patient, think about a 75-year-old with extreme anemia, as well as proximity to a clinic. Many of these patients have trouble coming into the clinic every three or four weeks for their injection of their infusion of the spatterceptor metal statin. So that's how one could envision then an interesting kind of frontline share that could then be supplemented with the additional data generation down the road.
Jay Olson
Analyst, Oppenheimer
Thank you. That's super helpful. I really appreciate the comprehensive overview and thanks for taking the questions.
Conference Operator
Operator
No, thank you, Jay. Thank you. Our next question comes from the line of Daniel Brim of Lake Street. Please go ahead, Daniel.
David DeLucia
Chief Financial Officer
Thanks. Thanks for taking the question. You know, sorry to see, you know, you need to do this pivot. The question I have is when FDA had reviewed roxidustat before, you know, they had pause with the thromboembolic events. With the increased number of the safety database from commercial use, have you figured out, you know, mitigation strategies around that, or have your discussions with the FDA when designing the Phase III, are they more comfortable with that AEP profile?
Thane Wettig
Chief Executive Officer
Yeah, thanks, Dan. Good to hear from you. I'm going to start, and I'm going to hand it over to Carrie, and then perhaps Carol after that. And I'm going to get into a little detail here, so apologies for that, but I think it's important context. And I'm going to touch on the CRL for CKD in the U.S., and that CRL was exclusively around what the FDA believed was too rapid of a rate of rise of hemoglobin, too high of a target for that then led to an imbalance in thromboembolic events. And so when we approached the agency through the type C meeting process, one of the most important questions we had to ask them based upon their perspective of Roxidus that are in the entire hip class in thromboembolic events, were they comfortable with us starting another phase three trial in MDS using the same starting dose and maximum dose and similar titration algorithm as in the previous phase three MDS trial Our feeling was that if they were really concerned about roxidustat and hemoglobin rate of rise and thromboembolic events, that they would ask us to go back and do some additional dose-finding work, perhaps use a lower starting dose than we used in the previous MDS trial. And we asked very specifically, are you aligned with the 2.5 mg per kg starting dose and a maximum of 3.5 mg per kg dose starting? as used in the previous MDS trial. And they came back and they said, unequivocally, yes. So that was a really important outcome for us through that type C process. And I'm going to ask, I think, Carrie to talk about the interaction with the agency and what we've done from a exclusion perspective to ensure that we are not only meeting the FDA's guidance here, but also making sure that we've got the opportunity to get a real good answer with respect to Roxidustep for its efficacy and its safety profile. Carrie?
Dr. Carrie Brownstein
Project Chief Financial Officer
Thank you, Thane. Yeah, we had a really fruitful discussion with the FDA around this. As Thane pointed out, there was no objection to our starting dose and our titration schedule. Importantly, while We wanted to make sure that we don't see a significant risk of thrombotic and cardiovascular events. We did work closely with the agency to kind of tighten up some of the eligibility criteria and ensure we're not over enrolling for patients who have a history of having multiple events or have a higher likelihood than your average MDS patient for an event. I think it's also important to point out just the background rate. You know, we already know that in MDS patients, there's a 2% to 3% risk of thrombotic and cardiovascular events overall. And what we've seen from the Matterhorn study is in line with what we've seen with other treatments in this patient population, including Lispatercept, which showed an incidence of around 5% and ESAs. has seen even 10%. So we expect that Roxadustat will be in the range seen with other agents in this class in this area for MDS and also these other ones are approved and they're also recommended for use. So I think we're in good shape there and we're expecting to enroll nicely and and these additional eligibility will actually really be helpful for the study.
Thane Wettig
Chief Executive Officer
Okay, Carol, anything to add to that? No additions from my side. Okay, thanks, Carol. Dan, other questions?
David DeLucia
Chief Financial Officer
No, I mean, that's all I have right now.
Thane Wettig
Chief Executive Officer
Okay, thank you.
Conference Operator
Operator
Thank you. Our next question comes from the line of Michael Kunwich of Maxim Group. Your line is open, Michael.
Michael Kunwich
Analyst, Maxim Group
Hey, guys. Thank you for taking my questions today.
Michael Kunwich
Analyst, Maxim Group
I wanted to ask just a little bit about the decision to go after the high transfusion burden patients, and in particular, why it's a good target. Does this have more to do with the unmet need and the Thank you, Michael.
Thane Wettig
Chief Executive Officer
Good to hear from you. I'll kick it off and then I'll turn it over to Carrie. I think it's really informed by a couple of things. One is, if you look at the Matterhorn trial, the reason the trial did not hit the primary endpoint is because of the high placebo response in the patients who required less than four units in the eight weeks leading up to the trial. It had a placebo response in that group that was extremely high. And it was a very consistent placebo response rate that was seen in the MEDLIS trial for luspatercept in patients who also required less than four units. So luspatercept studied patients two to six in their MEDLIS trial in that second line setting. they really got the maximum benefit in those patients who required at least four up to six. They had an extremely high placebo response. And so there's no scientific rationale for ronxidustatin in the HTV population. It's really a matter of making sure that we can conduct a trial that gives us the best chance of success from a clinical perspective that also is a very, very meaningful commercial opportunity as well. There's a substantial unmet need to get these patients who require four or more units over two consecutive eight-week periods of time down much lower than that or down to zero. And we know that when you look at that patient population, the placebo response is very low. It ranges anywhere from three, 4% up to 15%. And so what we've done is we've assumed a powering of our trial of a placebo response in that higher transfusion burden population of about 12%, knowing that we can drive substantial difference in absolute terms of transfusion independence with Rox-Dustat just based upon what we learned from the Matterhorn trial. Let me turn it over to Carrie because I'm sure she has some additional points to add to that.
Dr. Carrie Brownstein
Project Chief Financial Officer
Yeah, no, Thane, I think you hit all of them. You know, it's really yes and yes in the sense that the four units or higher patients do have a higher unmet medical need, and then also it is a defined Subgroup, which I think where the, if you look at the IWG criteria, the most recent ones, the four units or higher are considered the high transfusion burden and the endpoints that are recommended for the different transfusion burden levels are different. So from a just study design perspective, it makes sense to start at the four and use that patient population. Yeah.
Thane Wettig
Chief Executive Officer
Carol, do you have anything to add to that? No additions. Okay. What else, Michael?
Michael Kunwich
Analyst, Maxim Group
I also just want to ask a little bit about the safety and the differential in the grade 3s and the serious TAs between placebo and ROXA and why you expect that that difference didn't really translate into a difference in treatment discontinuation. Do you think that suggests the actual unmet need here and the desire for an oral option that actually works?
Thane Wettig
Chief Executive Officer
Yeah. Carrie, I'll pass that one over to you.
Dr. Carrie Brownstein
Project Chief Financial Officer
It's all of the above in the sense that yes, I think patients who are higher transfusion burden just generally are usually had their disease a little bit longer. They have more underlying medical conditions and are not surprisingly having more SAEs and some more grade threes. The likelihood is twofold. One is yes, they're more willing to have stay on drug because there's a need and a desire for an oral option. And I think also, too, is a lot of it probably has nothing to do with the drug, but they would have discontinued if it would have helped. So I think that's really a combination of those factors.
Thane Wettig
Chief Executive Officer
And Carrie, if you could also speak to, you know, Michael, we did see some grade three cardiovascular events as well. Carrie, speak to the discontinuation slash continuation of study drug population.
Dr. Carrie Brownstein
Project Chief Financial Officer
Yeah, this is important, too, and this came up with the other cardiovascular question. So we did see an imbalance in cardiovascular and thrombotic events in the study. What was interesting, again, it's a small patient, a small end study. So even though there was imbalance, the total number of patients with a significant event were only eight. and of those eight, six of those eight actually paused, had their event, their thrombosis or whatever they were dealing with resolved and they were actually able to restart medication without any additional problems. I think two of them actually stayed on drug and didn't even pause while they were resolving their thrombotic events. So I think again, it's a combination of both of these factors that A, some of the events were probably not had nothing to do with drug, and B, there's a desire to stay on drug and improve hemoglobin, decrease transfusions, despite having some issues, maybe having some issues due to the unmet needs.
Thane Wettig
Chief Executive Officer
Yeah, and Carrie, you're a hematologist oncologist. Can you speak to that specialty's ability to handle these types of adverse events in the clinic?
Dr. Carrie Brownstein
Project Chief Financial Officer
Yeah, I mean, this is like is bread and butter for these, I think, and this is a good difference potentially between when we were talking about the earlier CKD versus Hemonc. Hematologists who were dealing with this disease are used to taking care of patients who have thrombotic events and or are at risk with thrombotic events, and it's not something that the potential prescribers and PIs for our study are worried about. This is something that they can handle very easily and do not consider this a reason to not give drugs to their patients.
Michael Kunwich
Analyst, Maxim Group
All right. Thank you. I appreciate the additional clarity.
Thane Wettig
Chief Executive Officer
Yeah. Thank you, Michael, for the question.
Conference Operator
Operator
Thank you. I would now like to turn the conference back to Thane Wettig for closing remarks.
Thane Wettig
Chief Executive Officer
Yeah. Thanks, Lateef, guys, and everybody. Thank you for joining us for today's third quarter 2026 earnings call. and for your continued interest in contra Bio. Enjoy the rest of your day. Thanks, everyone.
Conference Operator
Operator
This concludes today's conference call. Thank you for participating.
Thane Wettig
Chief Executive Officer
You may now disconnect.